Executive Management

Christine Lind
CEO

Employed: 2024

Born: 1974

Education: Bachelor of Science in Finance and Information Systems, New York University, Stern School of Business. Masters in Business Administration in Finance and Management, Columbia Business School.

Previous assignments: Management roles in the life sciences industry, including VP Business Development at LifeCell Corporation, EVP Business Development and subsequently CEO of Medivir AB, Strategic Advisor to BioArctic AB, and most recently, SVP Corporate Development for SSI Strategy. Chairman of the Board, Mendus AB. Prior to that, as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co).

Other assignments: Member of the Board, Xspray Pharma AB. Chairman and CEO, Lind Growth Strategy AB.

Shareholdings: 389 500 B-shares as a personal holding
Patrick Bach
CFO

Employed: 2023

Born: 1983

Education: MSc in Finance and Strategic Management from Copenhagen Business School with graduating MSc courses at Columbia Business School, Harvard University, and The London School of Economics and Political Science. BSc in Economics and Business Administration from Copenhagen Business School.

Previous assignments: Various managerial positions at Atos Medical AB, most recently Managing Director Nordics and Vice President Consumer. Prior to that, several managerial positions at Coloplast, including Head of Strategy Wound Care, and Associate at McKinsey & Company as well as a Business Analyst at Novo Nordisk A/S.

Other assignments: –

Shareholdings: 320,000* B-shares via a capital insurance with a company controlled by Patrick Bach , as beneficiary (* holding per 26 March 2026)
Nathaniel Bachrach
Chief Scientific Officer

Born: 1966

Education: Doctor of Philosophy (Ph.D.) in Mechanical Engineering from Columbia University. Master and Bachelor of Science, Mechanical Engineeringat at Columbia University. Bachelor of Science, Physics at Yeshiva University.

Previous assignments:  25+ years of experience developing products for global commercialization in plastic reconstructive and general surgery, orthopaedics, and periodontics. Previous assignments were Executive Vice President and Chief Scientific Officer at 3DBio Corporation and Vice President Research & Technology at LifeCell Corporation. Prior to that various leadership and technical roles within LifeCell and Organigenesis Inc. He also has extensive experience and an impressive record of publications and innovative patents within Bactiguard’s strategic therapeutic areas.

Other assignments:  Consulting EVP, Strategy, Science & Product at PrintBIo
Kajsa Björklund
Executive vice president Research & Development

Employed: 2025

Born: 1973

Education: Ph.D. in Inorganic Chemistry from Uppsala University, M Sc in Chemistry from Uppsala University, Executive MBA from Mgruppen Svenska Managementgruppen

Previous Assignments: Management roles mainly in MedTech and the life science industry, including Director Portfolio Management at Seco Tools, Vice President Operations and R&D at OssDsign, and Director Project Management, Global R&D at Thermo Fisher Scientific. Earlier roles include Manager Design Transfer and Labeling at Thermo Fisher Scientific and different project management roles at Phadia, Semcon, and Orexo.

Other Assignments: –

Shareholdings: –
Clément Bègue
Executive Vice President Data & Intelligence

Employed: 2024

Born: 1986

Education: MBA in International Administration and Management, Paris. Master’s Degree in Public Law, Réunion.

Previous assignments: Director Business Intelligence & Commercial Insights, Atos Medical (part of Coloplast Group). Previous roles include Director Commercial Insights, Head of Commercial Insights, Global Commercial Insights Manager and Commercial Insights Manager.

Other assignments: –

Shareholdings: –
Ian Christensen
Senior Vice President Wound Management

Employede: 2025

Born: 1973

Education: MSc in international development studies and business economics from Roskilde University. Executive MBA from Copenhagen Business School.

Previous assignments: More than 20 years experience within the life science industry.

Various finance and investor relations positions in TDC and Novozymes. VP Investor relations, Country manager South Africa and Sub Saharan Africa and most recently VP with responsibly for Wound Management in China at Coloplast.

Other assignments: –

Shareholdings: –
Sophie Dahan
Executive Vice President, Business Development & Alliance Management

Employed: 2012

Born: 1965

Education: Bachelor of Science in Industrial Engineering from he Technion, Israel institute of Technology. MBA in Finance and Management from Tel Aviv University.

Previous assignments: Management roles at Bactiguard AB, including VP Alliance Management, General Manager Licensing and General Manager, driving strategic partnerships and commercial expansion, and supporting business development activities. Prior to that, several Project Manager roles, and Senior Analyst at Leumi Bank / Psagot Investment House, with focus on system implementation and financial analysis.

Other assignments: –

Shareholdings: –
Alf Laurell
Executive Vice President, Regulatory & Quality

Employed: 2025

Born: 1981

Education: M.Sc. Chemical Enngineering, Lund Institute of Technology

Previous assignments: Director of Quality & Regulatory Affairs, Scibase AB. Regulatory Affairs roles within Elekta.

Other assignments: –

Shareholdings: –

Christine Lind

Patrick Bach

Nathaniel Bachrach

Kajsa Björklund

Clément Bègue

Ian Christensen

Sophie Dahan

Alf Laurell